Scholar Rock

Scholar Rock SRRK Stock

$50.47   5.145836%
Add to favorites
Market Cap
$6.16B
LOW - HIGH [24H]
$47.95 - $50.62
VOLUME [24H]
$753.35K
P/E Ratio
0
Earnings per share
-$3.23
ISIN
US80706P1030
Price   Prediction

Scholar Rock Price Chart

Sorry, that's all we've gotfor now...

Scholar Rock (SRRK) stock price today is 50.47 USD on Tech Market Large (+5.15% on the day). Updated .

Scholar Rock SRRK Financial and Trading Overview

Scholar Rock stock price 50.47 USD
Previous Close 44.54 USD
Open 43.8 USD
Bid 44.8 USD x 200
Ask 55.65 USD x 200
Day's Range 43.32 - 45.19 USD
52 Week Range 37.54 - 61.76 USD
Volume 2.33M USD
Avg. Volume 1.81M USD
Market Cap 5.5B USD
Beta (5Y Monthly) 0.788
PE Ratio (TTM) N/A
EPS (TTM) -3.23 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 70.06 USD

SRRK Valuation Measures

Enterprise Value 5.29B USD
Trailing P/E N/A
Forward P/E -18.811
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 9649.057
Price/Book (mrq) 32.595806
Enterprise Value/Revenue 9279.572
Enterprise Value/EBITDA -12.978

Trading Information

Scholar Rock Stock Price History

Beta (5Y Monthly) 0.788
52-Week Change 13.58%
S&P500 52-Week Change 10.51%
52 Week High 61.76 USD
52 Week Low 37.54 USD
50-Day Moving Average 45.67 USD
200-Day Moving Average 48.23 USD

SRRK Share Statistics

Avg. Volume (3 month) 1.81M USD
Avg. Daily Volume (10-Days) 1.86M USD
Shares Outstanding 122M
Float 104.3M
Short Ratio 13.37
% Held by Insiders 0.72%
% Held by Institutions 123.66%
Shares Short 23.48M
Short % of Float 24.01%
Short % of Shares Outstanding 19.25%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -71732.27%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -59.58%
Return on Equity (ttm) -199.97%

Income Statement

Revenue (ttm) 570K USD
Revenue Per Share (ttm) 0.005 USD
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) -210488992 USD
EBITDA -407559008 USD
Net Income Avi to Common (ttm) -413609984 USD
Diluted EPS (ttm) -3.23
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 413.6M USD
Total Cash Per Share (mrq) 3.39 USD
Total Debt (mrq) 202.99M USD
Total Debt/Equity (mrq) 120.35 USD
Current Ratio (mrq) 5.409
Book Value Per Share (mrq) 1.383

Cash Flow Statement

Operating Cash Flow (ttm) -309711008 USD
Levered Free Cash Flow (ttm) -168629744 USD

Profile of Scholar Rock

Country United States
State MA
City Cambridge
Address 301 Binney Street
ZIP 02142
Phone 857 259 3860
Website https://www.scholarrock.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 289

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Q&A For Scholar Rock Stock

What is a current SRRK stock price?

Scholar Rock SRRK stock price today per share is 50.47 USD.

How to purchase Scholar Rock stock?

You can buy SRRK shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Scholar Rock?

The stock symbol or ticker of Scholar Rock is SRRK.

Which industry does the Scholar Rock company belong to?

The Scholar Rock industry is Biotechnology.

How many shares does Scholar Rock have in circulation?

The max supply of Scholar Rock shares is 122M.

What is Scholar Rock Price to Earnings Ratio (PE Ratio)?

Scholar Rock PE Ratio is now.

What was Scholar Rock earnings per share over the trailing 12 months (TTM)?

Scholar Rock EPS is -3.23 USD over the trailing 12 months.

Which sector does the Scholar Rock company belong to?

The Scholar Rock sector is Healthcare.

Scholar Rock SRRK included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24201.34 USD —
-0.94
4.68B USD — 24005.47 USD — 24939.62 USD — — 4.68B USD —
us US Tech Global Select Market Com NQGS US 11949.46 USD —
-0.71
— — 11825.17 USD — 12288.24 USD — — — —
us US Tech Biotechnology NBI US 6965.89 USD —
-0.08
— — 6905.76 USD — 7033.67 USD — — — —
us US Tech Health Care IXHC US 1317.49 USD —
-0.52
— — 1309.03 USD — 1333.62 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
$2.17T
Total marketcap
$71.79B
Total volume
BTC 58.07%   •   ETH 9.95%
Dominance
Select currency